MARKET

ACHFF

ACHFF

Arch Biopartners
OTCMQB
0.656
+0.022
+3.47%
Closed 15:03 02/11 EST
OPEN
0.655
PREV CLOSE
0.634
HIGH
0.656
LOW
0.650
VOLUME
4.00K
TURNOVER
2.62K
52 WEEK HIGH
1.410
52 WEEK LOW
0.520
MARKET CAP
43.91M
P/E (TTM)
-38.5882
1D
5D
1M
3M
1Y
5Y
1D
Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD
TipRanks · 3d ago
Arch Biopartners Advances IL-32 Drug Candidate Toward Clinical Trials for Diabetic Kidney Disease
Reuters · 3d ago
Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease
Barchart · 3d ago
Arch Biopartners posts FY net loss of USD 1.6 million and cash flow from financing activities of USD 1.6 million
Reuters · 01/29 05:10
Arch Biopartners Appoints Dr. Patrick Vink as Chairman of the Board
Reuters · 01/16 13:15
ARCH BIOPARTNERS ANNOUNCES APPOINTMENT OF DR. PATRICK VINK AS CHAIRMAN OF THE BOARD
Reuters · 01/16 13:15
Arch granted ethics approval for St. Michaels participation in Phase II trial
TipRanks · 12/16/2025 12:45
Arch Biopartners Wins Ethics Approval for Phase II Cardiac Surgery-Associated AKI Trial at St. Michael’s Hospital
Reuters · 12/16/2025 12:40
More
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

Webull offers Arch Biopartners Inc stock information, including OTCMQB: ACHFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHFF stock methods without spending real money on the virtual paper trading platform.